AU2017203436B2 — Compositions and methods for modulating apolipoprotein c-iii expression
Assigned to Ionis Pharmaceuticals Inc · Expires 2018-10-18 · 8y expired
What this patent protects
Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein C-Ill (ApoClil). In certain embodiments, the ApoClil targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targetin…
USPTO Abstract
Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein C-Ill (ApoClil). In certain embodiments, the ApoClil targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting ApoClIl for use in decreasing ApoClIl to treat, prevent, or ameliorate diseases, disorders or conditions related to ApoClIl. Certain diseases, disorders or conditions related to ApoClIl include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.